Banner_Corporate_v2_1

We Innovate Healthcare

At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives - from early detection and prevention of disease, to diagnosis, treatment and treatment monitoring.

We strive to address unmet medical needs through excellence in science and research. Roche's personalised healthcare approach uses new molecular insights to better tailor medicines and diagnostics to patients needs. With our combined strengths in pharmaceuticals and diagnostics, no company is better suited to this task.

www.roche.com
Personalized Healthcare


2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
0007507_crystalball

Diagnostics

Roche Diagnostics NZ Ltd is based in Mt Wellington, Auckland and is a leading supplier of laboratory solutions, instrument systems, tests, software and services that help laboratories deliver reliable results more efficiently and cost-effectively.

Roche Diagnostics is active in all market segments, from scientific research and clinical laboratory systems to patient self-monitoring

Roche Dignostics Business Overview

Diagnostics



lowres9577cobas8000

Pharmaceuticals

Roche Products NZ Ltd is the pharmaceutical division of Roche based in Newmarket, Auckland.

Roche supports research and education for New Zealand clinicians and patients.  As the leading provider of oncology medicines in New Zealand, Roche makes a significant contribution to the management of patients with cancer.  Roche’s broad portfolio also provides  innovative medicines in areas such as rheumatoid arthritis and hepatitis.

Full list of Roche medicines
Roche-Plus healthcare professionals website
CancerNZ patient website


0007511